---
title: "Key facts: Enhertu Cleared for Two Breast Uses; Safety Flag on AZ RSV"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286637657.md"
description: "FDA cleared Enhertu for two more Stage 2–3 breast cancer uses. AstraZeneca co-develops/commercializes the drug and owes Daiichi Sankyo a $155M milestone; U.S. sales credited to Daiichi Sankyo.1FDA official Tracey Hoeg flagged safety questions about AstraZeneca PLC's infant RSV preventive during agency review of RSV treatments, prompting renewed regulatory scrutiny relevant to AZN traders.2"
datetime: "2026-05-16T07:14:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286637657.md)
  - [en](https://longbridge.com/en/news/286637657.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286637657.md)
---

# Key facts: Enhertu Cleared for Two Breast Uses; Safety Flag on AZ RSV

-   FDA cleared Enhertu for two more Stage 2–3 breast cancer uses. AstraZeneca co-develops/commercializes the drug and owes Daiichi Sankyo a $155M milestone; U.S. sales credited to Daiichi Sankyo.1
-   FDA official Tracey Hoeg flagged safety questions about AstraZeneca PLC's infant RSV preventive during agency review of RSV treatments, prompting renewed regulatory scrutiny relevant to AZN traders.2

### Related Stocks

- [DSNKY.US](https://longbridge.com/en/quote/DSNKY.US.md)
- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)
- [4568.JP](https://longbridge.com/en/quote/4568.JP.md)

## Related News & Research

- [Enhertu® Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast Cancer | AZN Stock News](https://longbridge.com/en/news/286621973.md)
- [AstraZeneca Gets U.S. Approval for Hypertension Drug](https://longbridge.com/en/news/286724028.md)
- [AstraZeneca Scores Key FDA Wins Across Cardiovascular And Oncology Portfolios](https://longbridge.com/en/news/286801629.md)
- [FDA approves Enhertu for two HER2-positive early breast cancer indications](https://longbridge.com/en/news/286740066.md)
- [AZN :FDA Approves ENHERTU For HER2-Positive Early Breast Cancer In Neoadjuvant And Adjuvant Settings](https://longbridge.com/en/news/286677080.md)